Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af HLD-0915 hos patienter med metastatisk kastrationsresistent prostatacancer (MCRPC)

2. november 2026 opdateret af: Janssen Research & Development, LLC

Fase 1/2 undersøgelse af HLD-0915 hos patienter med metastatisk kastrationsresistent prostatacancer (MCRPC)

Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

190

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Sutton, Det Forenede Kongerige, SM2 5PT
        • Rekruttering
        • The Royal Marsden NHS Trust
    • Colorado
      • Colorado Springs, Colorado, Forenede Stater, 80909
        • Rekruttering
        • Rocky Mountain Cancer Center
      • Denver, Colorado, Forenede Stater, 80218
        • Rekruttering
        • Sarah Cannon Research Institute 1
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06511
        • Rekruttering
        • Yale University
    • Florida
      • Sarasota, Florida, Forenede Stater, 34232
        • Rekruttering
        • Florida Cancer Specialists
    • Louisiana
      • Metairie, Louisiana, Forenede Stater, 70006
        • Rekruttering
        • XCancer Research Network LCMC Health EJGH
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Rekruttering
        • Dana Farber Mass General Brigham Cancer Care Inc
    • Michigan
      • Grand Rapids, Michigan, Forenede Stater, 49546
        • Rekruttering
        • South Texas Accelerated Research Therapeutics, LLC (START)
    • Nebraska
      • Omaha, Nebraska, Forenede Stater, 68130
        • Rekruttering
        • Urology Cancer Center, PC
    • New York
      • Long Island City, New York, Forenede Stater, 11101
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center
      • Syracuse, New York, Forenede Stater, 13210
        • Rekruttering
        • Associated Medical Professionals
    • North Carolina
      • Durham, North Carolina, Forenede Stater, 27710
        • Rekruttering
        • Duke University Medical Center
    • South Carolina
      • Myrtle Beach, South Carolina, Forenede Stater, 29572
        • Rekruttering
        • Carolina Urologic Research Center
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37203
        • Rekruttering
        • Sarah Cannon Research Institute
      • Nashville, Tennessee, Forenede Stater, 37209
        • Rekruttering
        • Urology Associates
    • Texas
      • Austin, Texas, Forenede Stater, 78758
        • Rekruttering
        • NEXT Oncology
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • MD Anderson Cancer Center
    • Virginia
      • Norfolk, Virginia, Forenede Stater, 23502
        • Rekruttering
        • Virginia Clinical Research

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Han

Beskrivelse

Patients must meet the following criteria to be eligible study participation:

Key Inclusion Criteria:

All Study Arms (Phase 1 Part 1 & 2, Phase 2 Part 1, Part 2A, 2B, 2C & 2D):

Males ≥ 18 years old Histological, pathological, and/or cytological confirmation of prostate adenocarcinoma Adequate hematological, renal, and hepatic function. Able to swallow oral medication

mCRPC Arms: (Phase 1 Part 1 & 2, Phase 2 Part 1): Prior orchiectomy or ongoing androgen-deprivation therapy and a castrate level of serum testosterone Progressive mCRPC defined as having demonstrated PSA progression on the prior regimen

SOAR Arm (Phase 2 Part 2A) mHSPC with distant metastatic disease based on conventional imaging PSA ≥0.2 ng/mL, following treatment with next generation ARPI for at least 180 days and up to 365 days No evidence of radiographic or PSA progression while receiving ARPI

mHSPC arms (Phase 2 Part 2B, 2C & 2D) serum testosterone >150ng/ml mHSPC with distant metastatic disease based on conventional imaging and PSA >2.0 ng/mL

Key Exclusion Criteria:

All arms (Phase 1 Part 1 & 2, Phase 2 Part 1, Part 2A, 2B, 2C & 2D):

Has experienced a recent major bleed or has a known bleeding disorder Tumors exhibiting neuroendocrine or small cell carcinoma component by histopathology Receiving continuous corticosteroids at prednisone-equivalent dose of >10 mg/day Prior or ongoing significant medical condition

mCRPC arms: (Phase 1 Part 1 & 2, Phase 2 Part 1): Has received systemic anti-cancer therapy or investigational drugs within 2 weeks prior to first dose of study drug with certain exceptions requiring longer washout periods

SOAR arm (Phase 2 Part 2A) Has received any prior cytotoxic chemotherapy for prostate cancer

mHSPC arms (Phase 2 Part 2B, 2C & 2D) regional pelvic lymph node disease only

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: JNJ-101556143 Phase 1 Part 1 - Dose Escalation

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

Eksperimentel: JNJ-101556143 Phase 1 Part 2 - Formulation Exploration

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

Experimental: Oral JNJ-101556143

Experimental: Oral JNJ-101556143

Eksperimentel: JNJ-101556143 Phase 2 Part 1 - Dose Optimization

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

Eksperimentel: Phase 2 Part 2A - SOAR

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

Eksperimentel: Phase 2 Part 2B - HSPC Expansion

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

Eksperimentel: Phase 2 Part 2C - HSPC Expansion

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

Eksperimentel: Phase 2 Part 2D - HSPC Expansion

Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Experimental: Oral JNJ-101556143

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Frequency of dose-limiting toxicities (DLTs)
Tidsramme: 21 days
21 days
Frequency and severity of AEs and abnormal ECG, laboratory and clinical changes since baseline
Tidsramme: 21 days
21 days
Phase 1 Part 2 (formulation exploration) relative bioavailability
Tidsramme: 22 days
22 days

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
PK Parameters
Tidsramme: 21 days
21 days
Duration of Response (DOR)
Tidsramme: 21 days
21 days
Radiographic Progression-Free Survival (rPFS)
Tidsramme: 63 days
63 days
Time to Response (TTR)
Tidsramme: 63 days
63 days
Change in PSA over time
Tidsramme: 21 days

Including PSA50 and PSA90 response

21 days
Objective Response Rate (ORR)
Tidsramme: 63 days

Per RECIST in evaluable patients

63 days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

6. februar 2025

Primær færdiggørelse (Anslået)

17. august 2028

Studieafslutning (Anslået)

17. august 2028

Datoer for studieregistrering

Først indsendt

20. januar 2025

Først indsendt, der opfyldte QC-kriterier

27. januar 2025

Først opslået (Faktiske)

30. januar 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • HLD-0915-ONC-101
  • HLD-0915-ONC-101 (Anden identifikator: Janssen Research & Development, LLC)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .